555 related articles for article (PubMed ID: 33947692)
21. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Rimawi MF; De Angelis C; Contreras A; Pareja F; Geyer FC; Burke KA; Herrera S; Wang T; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Krop IE; Wolff AC; Pavlick AC; Fuqua SAW; Gutierrez C; Hilsenbeck SG; Li MM; Weigelt B; Reis-Filho JS; Kent Osborne C; Schiff R
Breast Cancer Res Treat; 2018 Feb; 167(3):731-740. PubMed ID: 29110152
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Loibl S; Majewski I; Guarneri V; Nekljudova V; Holmes E; Bria E; Denkert C; Schem C; Sotiriou C; Loi S; Untch M; Conte P; Bernards R; Piccart M; von Minckwitz G; Baselga J
Ann Oncol; 2016 Aug; 27(8):1519-25. PubMed ID: 27177864
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T; Tsurutani J; Takahashi M; Yamanaka T; Sakai K; Ito Y; Fukuoka J; Kimura H; Kawabata H; Tamura K; Matsumoto K; Aogi K; Sato K; Nishio K; Nakagawa K; Saeki T
Breast; 2018 Aug; 40():67-75. PubMed ID: 29698927
[TBL] [Abstract][Full Text] [Related]
24. Patient-Reported Outcomes in Patients With
Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
[TBL] [Abstract][Full Text] [Related]
25. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Hoste G; Slembrouck L; Jongen L; Punie K; Matton T; Vander Borght S; Vanden Bempt I; Menten J; Wildiers H; Floris G; Arteaga C; Neven P
Clin Drug Investig; 2018 Nov; 38(11):1071-1075. PubMed ID: 30187361
[TBL] [Abstract][Full Text] [Related]
26. Alpelisib for the treatment of
Leenhardt F; Alexandre M; Jacot W
Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
[No Abstract] [Full Text] [Related]
27. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience.
Sarfraz H; Bari S; Whiting J; Sur M; Mo Q; Armitage M; Costa RLB
Oncology; 2024; 102(5):414-424. PubMed ID: 38011835
[TBL] [Abstract][Full Text] [Related]
28. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
[TBL] [Abstract][Full Text] [Related]
29. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
Baselga J; Gelmon KA; Verma S; Wardley A; Conte P; Miles D; Bianchi G; Cortes J; McNally VA; Ross GA; Fumoleau P; Gianni L
J Clin Oncol; 2010 Mar; 28(7):1138-44. PubMed ID: 20124182
[TBL] [Abstract][Full Text] [Related]
31. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
[TBL] [Abstract][Full Text] [Related]
32. Alpelisib: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
[TBL] [Abstract][Full Text] [Related]
33. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Vuylsteke P; Huizing M; Petrakova K; Roylance R; Laing R; Chan S; Abell F; Gendreau S; Rooney I; Apt D; Zhou J; Singel S; Fehrenbacher L
Ann Oncol; 2016 Nov; 27(11):2059-2066. PubMed ID: 27573562
[TBL] [Abstract][Full Text] [Related]
34. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D; Gonçalves A; De La Motte Rouge T; Akla S; Blonz C; Grenier J; Gligorov J; Saghatchian M; Bailleux C; Simon H; Desmoulins I; Tharin Z; Renaud E; Bertho M; Benderra MA; Delaloge S; Robert L; Cottu P; Pierga JY; Loirat D; Bertucci A; Renouf B; Bidard FC; Lerebours F
Oncogene; 2023 Jun; 42(23):1951-1956. PubMed ID: 36611120
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Fiascarelli A; Merlino G; Capano S; Talucci S; Bisignano D; Bressan A; Bellarosa D; Carrisi C; Paoli A; Bigioni M; Tunici P; Irrissuto C; Salerno M; Arribas J; de Stanchina E; Scaltriti M; Binaschi M
Breast Cancer Res Treat; 2023 May; 199(1):13-23. PubMed ID: 36913051
[TBL] [Abstract][Full Text] [Related]
37. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
[TBL] [Abstract][Full Text] [Related]
40. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
